During the recent session, Zomedica Corp (AMEX:ZOM)’s traded shares were 11.2 million, with the beta value of the company hitting 1.03. At the last check today, the stock’s price was $0.15, reflecting an intraday gain of 8.90% or $0.01. The 52-week high for the ZOM share is $0.20, that puts it down -33.33 from that peak though still a striking 20.0% gain since the share price plummeted to a 52-week low of $0.12. The company’s market capitalization is $147.48M, and the average intraday trading volume over the past 10 days was 8.16 million shares, and the average trade volume was 5.84 million shares over the past three months.
Zomedica Corp (ZOM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. ZOM has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.01.
Zomedica Corp (AMEX:ZOM) trade information
Zomedica Corp (ZOM) registered a 8.90% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 8.90% in intraday trading to $0.15, hitting a weekly high. The stock’s 5-day price performance is 24.28%, and it has moved by 14.89% in 30 days. Based on these gigs, the overall price performance for the year is -19.86%. The short interest in Zomedica Corp (AMEX:ZOM) is 51.14 million shares and it means that shorts have 17.24 day(s) to cover.
Zomedica Corp (ZOM) estimates and forecasts
Statistics show that Zomedica Corp has underperformed its competitors in share price, compared to the industry in which it operates. Zomedica Corp (ZOM) shares have gone up 3.79% during the last six months, with a year-to-date growth rate less than the industry average at -150.00% against 15.30.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 8.1M as predicted by 1 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 7.78M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 27.70%. While earnings are projected to return -37.14% in 2025.
ZOM Dividends
Zomedica Corp is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Zomedica Corp (AMEX:ZOM)’s Major holders
Zomedica Corp insiders own 1.78% of total outstanding shares while institutional holders control 8.33%, with the float percentage being 8.48%. VANGUARD GROUP INC is the largest shareholder of the company, while 101.0 institutions own stock in it. As of 2024-06-30, the company held over 29.93 million shares (or 3.054% of all shares), a total value of $382.18 million in shares.
The next largest institutional holding, with 26.21 million shares, is of BLACKROCK INC.’s that is approximately 2.6742% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $334.65 million.
